GlassScriptPhysician profile
Douglas Frederick Smith
NPI 1578543195
$4,169.93
in general payments reported to CMS, 2019-2025
26 companies · $86.52 in 2025
The $86.52 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $354 · 2021: $1,238 · 2022: $841 · 2023: $357 · 2024: $181 · 2025: $86.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.34 | 2019-2023 | Lo Loestrin Fe |
| Exeltis, USA INC. | $690.41 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $405.29 | 2021-2025 | |
| Intuitive Surgical, INC. | $278.59 | 2019-2022 | |
| Myovant Sciences INC. | $174.67 | 2021-2022 | |
| Hologic Sales and Service, LLC | $169.35 | 2019-2024 | Acessa Provu System |
| Coopersurgical, INC. | $143.65 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $141.10 | 2019-2021 | |
| Therapeuticsmd, INC. | $136.37 | 2020-2022 | |
| Gynesonics, INC. | $134.04 | 2021 | |
| Evofem Biosciences, INC. | $103.07 | 2022-2025 | Solosec, Phexx, Phexxi |
| Avion Pharmaceuticals | $91.38 | 2019-2021 | |
| Scynexis, INC. | $76.93 | 2022 | |
| Astellas Pharma US INC | $73.05 | 2023 | Veozah |
| Pfizer INC. | $53.95 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $53.39 | 2019-2021 | |
| Shield Therapeutics INC | $50.04 | 2023-2024 | Accrufer |
| Allergan, INC. | $42.67 | 2019 | |
| Mylan Pharmaceuticals INC. | $30.16 | 2022 | |
| Covidien LP | $25.71 | 2019 | |
| Millicent US INC | $24.01 | 2024 | Femring, Intrarosa |
| Organon LLC | $19.70 | 2022 | |
| Merck Sharp & Dohme LLC | $17.98 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.84 | 2019 | |
| Biogen, INC. | $16.27 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.